Literature DB >> 17325833

Increasing evidence that the risks of rhAPC may outweigh its benefits.

Peter Q Eichacker, Charles Natanson.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17325833     DOI： 10.1007/s00134-007-0556-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  10 in total

Review 1.  Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

2.  Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Authors:  Peter Q Eichacker; Robert L Danner; Anthony F Suffredini; Xizhong Cui; Charles Natanson
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

3.  Substantiating the concerns about recombinant human activated protein C use in sepsis.

Authors:  Katherine J Deans; Peter C Minneci; Steven M Banks; Charles Natanson; Peter Q Eichacker
Journal:  Crit Care Med       Date:  2004-12       Impact factor: 7.598

4.  The value of phase 4 clinical testing.

Authors:  Gus J Vlahakes
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

5.  First, gather the data.

Authors:  David Hunter
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

6.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

7.  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Authors:  Jean-Louis Vincent; Gordon R Bernard; Richard Beale; Christopher Doig; Christian Putensen; Jean-Francois Dhainaut; Antonio Artigas; Roberto Fumagalli; William Macias; Theressa Wright; Kar Wong; David P Sundin; Mary Ann Turlo; Jonathan Janes
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

8.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

9.  Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

Authors:  Salmaan Kanji; Marc M Perreault; Clarence Chant; David Williamson; Lisa Burry
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

10.  Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.

Authors:  Guido Bertolini; Carlotta Rossi; Abramo Anghileri; Sergio Livigni; Antonio Addis; Daniele Poole
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440
  10 in total
  18 in total

1.  Is there increasing evidence that the risks of rhAPC may outweigh its benefits?

Authors:  Maria Plataki; Katerina Vaporidi; Dimitris Georgopoulos
Journal:  Intensive Care Med       Date:  2007-06-12       Impact factor: 17.440

2.  Mechanisms of sepsis and insights from clinical trials.

Authors:  Nitin Seam; Anthony F Suffredini
Journal:  Drug Discov Today Dis Mech       Date:  2007

3.  Once is not enough: clinical trials in sepsis.

Authors:  Daniel A Sweeney; Robert L Danner; Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

4.  Editors' comments on a new trial of activated protein C for persistent septic shock.

Authors:  Jordi Mancebo; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

Review 5.  Scientific and clinical challenges in sepsis.

Authors:  Luis Ulloa; Michael Brunner; Laura Ramos; Edwin A Deitch
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

6.  Early antimicrobial therapy in severe sepsis and septic shock.

Authors:  Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2010-09       Impact factor: 3.725

7.  Recently published papers: therapies failed, disputed, and beneficent.

Authors:  Gareth Williams
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

8.  The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.

Authors:  Greg Martin; Frank M Brunkhorst; Jonathan M Janes; Konrad Reinhart; David P Sundin; Kassandra Garnett; Richard Beale
Journal:  Crit Care       Date:  2009-06-30       Impact factor: 9.097

Review 9.  Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.

Authors:  Hartmut Weiler; Wolfram Ruf
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

Review 10.  Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

Authors:  Daniel De Backer
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.